Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244497884> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4244497884 abstract "OBJECTIVE: The gradual increase of persons living with HIV, mainly due to the reduced mortality achieved with effective antiretroviral therapies, calls for increased rationality and awareness in health resources consumption also during the early illness phases. Aim of this work is the estimation of the budget impact related to the variation in backbone prescribing trends in naïve patients. METHODS: Target population is the number of patients starting antiretroviral therapy each year, according to the Italian HIV surveillance registry, excluding patients receiving non-authorized or non-recommended regimens. We modeled 3-year mortality and durability rates on a dynamic cohort, basing on international literature. A prevalent patients analysis has also been conducted, for which the model is fed by a closed cohort consisting of all the patients without experience of virologic failure. The aim of this collateral analysis is to estimate the difference in current annual expenditures if the past prescription trends for patients starting therapy would have led to the evaluated hypothetical scenarios. Current Italian market shares of triple regimens containing first-choice or alternative backbones (tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine) are compared to three hypothetical scenarios (base-case, minimum and maximum) in which increasing shares of patients eligible to abacavir/lamivudine start first line treatment with this backbone. Annual cost for each regimen comprises drugs acquisition under hospital pricing rules, monitoring exams and preventive tests, valued basing on regional reimbursement tariffs. RESULTS: According to current prescribing trends, in the next three years about 13,000 patients starting HIV therapy will receive tenofovir/emtricitabine (83% of the target population), and minor portions other regimens (9% abacavir/lamivudine, 8% zidovudine/lamivudine). Patients that would be eligible to abacavir/lamivudine are 1.5, 4.5 and 6 thousand more than those presently treated according to the three hypothetical scenarios, leading to a cumulative saving of 850 thousand, 2.4 million and 3.3 million euro, respectively. If in the past the same modification of first line prescription trend was adopted, the annual current cost saving would vary from 922 thousands to 7.3 million euro. Most of this amount is due to reduced acquisition costs and, secondarily, to lower monitoring needs. CONCLUSION: Where patient features don’t force the choice of the backbone, abacavir/lamivudine prescription may induce substantial savings, allowing the release of resources needed to manage more complicated/advanced cases." @default.
- W4244497884 created "2022-05-12" @default.
- W4244497884 creator A5017150833 @default.
- W4244497884 creator A5017189389 @default.
- W4244497884 creator A5018497724 @default.
- W4244497884 creator A5024975408 @default.
- W4244497884 creator A5080933580 @default.
- W4244497884 date "2013-06-04" @default.
- W4244497884 modified "2023-09-30" @default.
- W4244497884 title "First-line HIV treatment: evaluation of backbone choice and its budget impact" @default.
- W4244497884 doi "https://doi.org/10.7175/fe.64314275-87" @default.
- W4244497884 hasPublicationYear "2013" @default.
- W4244497884 type Work @default.
- W4244497884 citedByCount "0" @default.
- W4244497884 crossrefType "journal-article" @default.
- W4244497884 hasAuthorship W4244497884A5017150833 @default.
- W4244497884 hasAuthorship W4244497884A5017189389 @default.
- W4244497884 hasAuthorship W4244497884A5018497724 @default.
- W4244497884 hasAuthorship W4244497884A5024975408 @default.
- W4244497884 hasAuthorship W4244497884A5080933580 @default.
- W4244497884 hasBestOaLocation W42444978841 @default.
- W4244497884 hasConcept C126322002 @default.
- W4244497884 hasConcept C142462285 @default.
- W4244497884 hasConcept C159047783 @default.
- W4244497884 hasConcept C177713679 @default.
- W4244497884 hasConcept C187212893 @default.
- W4244497884 hasConcept C194828623 @default.
- W4244497884 hasConcept C2522874641 @default.
- W4244497884 hasConcept C2777869810 @default.
- W4244497884 hasConcept C2778715236 @default.
- W4244497884 hasConcept C2779465607 @default.
- W4244497884 hasConcept C2779778239 @default.
- W4244497884 hasConcept C2780216070 @default.
- W4244497884 hasConcept C2780593183 @default.
- W4244497884 hasConcept C2780727368 @default.
- W4244497884 hasConcept C2781413609 @default.
- W4244497884 hasConcept C2908647359 @default.
- W4244497884 hasConcept C2993143319 @default.
- W4244497884 hasConcept C3013748606 @default.
- W4244497884 hasConcept C512399662 @default.
- W4244497884 hasConcept C71924100 @default.
- W4244497884 hasConcept C72563966 @default.
- W4244497884 hasConcept C99454951 @default.
- W4244497884 hasConceptScore W4244497884C126322002 @default.
- W4244497884 hasConceptScore W4244497884C142462285 @default.
- W4244497884 hasConceptScore W4244497884C159047783 @default.
- W4244497884 hasConceptScore W4244497884C177713679 @default.
- W4244497884 hasConceptScore W4244497884C187212893 @default.
- W4244497884 hasConceptScore W4244497884C194828623 @default.
- W4244497884 hasConceptScore W4244497884C2522874641 @default.
- W4244497884 hasConceptScore W4244497884C2777869810 @default.
- W4244497884 hasConceptScore W4244497884C2778715236 @default.
- W4244497884 hasConceptScore W4244497884C2779465607 @default.
- W4244497884 hasConceptScore W4244497884C2779778239 @default.
- W4244497884 hasConceptScore W4244497884C2780216070 @default.
- W4244497884 hasConceptScore W4244497884C2780593183 @default.
- W4244497884 hasConceptScore W4244497884C2780727368 @default.
- W4244497884 hasConceptScore W4244497884C2781413609 @default.
- W4244497884 hasConceptScore W4244497884C2908647359 @default.
- W4244497884 hasConceptScore W4244497884C2993143319 @default.
- W4244497884 hasConceptScore W4244497884C3013748606 @default.
- W4244497884 hasConceptScore W4244497884C512399662 @default.
- W4244497884 hasConceptScore W4244497884C71924100 @default.
- W4244497884 hasConceptScore W4244497884C72563966 @default.
- W4244497884 hasConceptScore W4244497884C99454951 @default.
- W4244497884 hasIssue "2" @default.
- W4244497884 hasLocation W42444978841 @default.
- W4244497884 hasLocation W42444978842 @default.
- W4244497884 hasOpenAccess W4244497884 @default.
- W4244497884 hasPrimaryLocation W42444978841 @default.
- W4244497884 hasRelatedWork W1993848347 @default.
- W4244497884 hasRelatedWork W1994809267 @default.
- W4244497884 hasRelatedWork W2003932723 @default.
- W4244497884 hasRelatedWork W2009577475 @default.
- W4244497884 hasRelatedWork W2023482069 @default.
- W4244497884 hasRelatedWork W2135690881 @default.
- W4244497884 hasRelatedWork W2271048306 @default.
- W4244497884 hasRelatedWork W2320051647 @default.
- W4244497884 hasRelatedWork W2736156591 @default.
- W4244497884 hasRelatedWork W5948707 @default.
- W4244497884 hasVolume "14" @default.
- W4244497884 isParatext "false" @default.
- W4244497884 isRetracted "false" @default.
- W4244497884 workType "article" @default.